

March 2016 DUR Board Meeting Minutes

Date: March 30, 2016

Members Present: Lisa Sather, Anglim, Caldwell, Burton, Fitzgerald, Maxwell, McGrane, and Harrison

Others Present: Dave Campana, Katie Hawkins, and Dan Peterson from Medicaid; Kathy Novak from Magellan; Woodmansey, Doppler, Barnhill, Artis from Drug Case Management; and representatives of drug manufacturers and the public.

Lisa Sather opened the meeting.

Public Comment:

There was no public comment.

Meeting Minute Review:

Meeting minutes from February were approved as written.

Department Update:

No Department update.

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2016 RECOMMENDATIONS
ACNE AGENTS-TOPICAL	Acnefree Severe [®] , Epiduo [®] Forte - ND	<ul style="list-style-type: none"> • <u>Benzoyl Peroxide Combos</u> – Class Effect. • <u>Benzoyl Peroxide Agents</u>– Class Effect. • <u>Clindamycin Agents</u> – Class Effect. • <u>Sodium Sulfacetamide Agents</u> – Class Effect. • <u>Azelaic Acid</u> – May add. • <u>Dapsone topical</u> – May add. • <u>Topical Retinoids & Combos</u> – Class Effect. • <u>Erythromycin topical</u> – Class Effect.
ANTIBIOTICS-GI	Xifaxan [®] -NI	Must have metronidazole and vancomycin-May add others.
ANTIBIOTICS-Vaginal	Nuversa [®] -ND	Therapeutic alternatives.
ANTIFUNGALS, ORAL	Cresemba [®] -ND Sporonox [®] -NI	Must have terbinafine and fluconazole; Must have 1 of clotrimazole or nystatin. May add others. Continue PA criteria on ketoconazole.
ANTIPARASITICS-TOPICAL	Natroba [®] -NI	Therapeutic alternatives. Continue PA criteria.
COPD AGENTS	Stiolto Respimat [®] , Seebri Neohaler [®] , Utibron Neohaler [®] -ND Tudorza [®] , Spiriva Respimat [®] -NI	Class effect. Must have nebulizer product. Continue PA Criteria on Daliresp.
CYOKINES & CAM ANTAGONIST	Cosentyx [®] -ND; Enbrel [®] , Humira [®] -NI	Therapeutic alternatives; Do not add anakinra (Kineret [®]) due to inferior efficacy and increased toxicity. Continue PA criteria for class (Physician specialist required for approval) Grandfather.
GLUCOCORTICOIDS, Inhaled	Breo Ellipta [®] -NI	Class effect.

HEPATITIS C AGENTS	Daklinza [®] , Technivie [®] , Zepatier [®] -ND Viekira Pak [®] , Olysio [®] , Harvoni [®] -NI	<u>Ribavirins</u> - Class effect; <u>Pegylated interferons</u> -Class effect; <u>All others</u> - Therapeutic alternatives. Continue with existing PA criteria. Grandfather.
IMMUNOSUPPRESSANTS Oral	Envarsus XR [®] -ND, Rapamune [®] -NI	Must have all chemical entities. Grandfather.
INTRANASAL RHINITIS AGENTS	Dymista [®] , Astepro [®] -NI Ticanase [®] -ND	<u>Nasal Steroids</u> -Class effect. <u>Nasal Antihistamines & others</u> - Class effect.
STEROIDS, Topical	DermacinRX Silapak [®] , DermacinRX Silazone [®] -ND	<u>LOW, MEDIUM, HIGH and VERY HIGH Potency classes</u> - Class Effect; must have 1 cream and 1 ointment from each category, may add other forms.

Board recommendations for Group 2 (Blue category) - This category of drugs has no new information since last review:

CLASS	2016 RECOMMENDATIONS
ANTIBIOTICS-Inhaled	Therapeutic alternatives.
ANTIBIOTICS-Topical	Must have a mupirocin product; may have retapamulin.
ANTIHISTAMINES, Minimally sedating	Class effect; must have one single ingredient agent.
ANTINEOPLASTIC AGENTS, Topical	Therapeutic alternatives.
ANTIPSORIATICS, Topical	Class effect; Must have one topical formulation and a scalp formulation. Continue PA criteria.
ANTIVIRALS, Oral	<u>HSV Antivirals</u> - Class effect. <u>INFLUENZA Antivirals</u> - Must have CDC recommended agents. May add others.
ANTIVIRALS-Topical	Class effect
BLADDER RELAXANTS	Class effect. Must have 1 long acting agent (either by half-life or dosage form)
BPH AGENTS	<u>ALPHA BLOCKERS</u> - Class effect. <u>ANDROGEN HORMONE INHIBITORS/COMBOS</u> -Class effect. <u>PDE-5 for BPH-tadalafil</u> will be non-preferred. Continue with PA criteria.
BRONCHODILATORS	<u>Beta Agonist, Long Acting</u> - class effect. <u>Beta Agonist, Short Acting</u> -class effect.
CEPHALOSPORINS & RELATED AGENTS	<u>2nd Generation</u> -class effect. <u>3rd Generation</u> -class effect.
EPINEPHRINE, Self Injected	Class effect.
FLUOROQUINOLONES, ORAL	<u>2nd Generation</u> -class effect; must have ciprofloxacin. <u>3rd Generation</u> - class effect.
GLUCOCORTICOIDS, Oral	<u>SHORT ACTING</u> ; cortisone, hydrocortisone - Therapeutic alternatives. <u>INTERMEDIATE ACTING</u> - methylprednisolone, prednisone, and prednisolone- Therapeutic alternatives, must include a dosepak. <u>LONG ACTING</u> - betamethasone, dexamethasone - Therapeutic alternatives. <u>BUDESONIDE</u> - Must have 1 budesonide.
HAE TREATMENT	Therapeutic alternatives.

IMMUNOMODULATORS-Atopic Dermatitis	Class effect-Must have one. Continue PA criteria.
IMMUNOMODULATORS-Topical	Class effect.
LEUKOTRINE MODIFIERS	Must have montelukast. May add zafirlukast.
MACROLIDES & KETOLIDES	Class effect-Must have azithromycin, clarithromycin and erythromycin.
METHOTREXATE AGENTS	Must have one oral and one injectable agent.
PHOSPHATE BINDERS	Class effect.
ROACEA AGENTS, Topical	Must have one metronidazole product; May add others.
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have Chantix®. May add others.
TETRACYCLINE	Must have doxycycline. May add others.

The next meeting is April 27, 2016 at the Great Northern. It will be the last Preferred Drug List meeting of 2016.

Meeting adjourned at 3:20.